1. Home
  2. SBLX vs JAGX Comparison

SBLX vs JAGX Comparison

Compare SBLX & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBLX

StableX Technologies Inc.

N/A

Current Price

$3.26

Market Cap

3.8M

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.19

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBLX
JAGX
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBLX
JAGX
Price
$3.26
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
110.3K
380.3K
Earning Date
11-14-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,785,000.00
Revenue This Year
N/A
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.45
52 Week Low
$2.32
$1.00
52 Week High
$15.28
$33.25

Technical Indicators

Market Signals
Indicator
SBLX
JAGX
Relative Strength Index (RSI) 46.29 41.39
Support Level $2.68 $1.05
Resistance Level $4.00 $1.36
Average True Range (ATR) 0.49 0.16
MACD 0.11 0.04
Stochastic Oscillator 42.65 38.00

Price Performance

Historical Comparison
SBLX
JAGX

About SBLX StableX Technologies Inc.

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: